Common use of Non-Royalty Sublicense Revenues Clause in Contracts

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC a percentage of these Non- Royalty Sublicense Revenues according to the following schedule: Date of Receipt of Non-Royalty Sublicense Revenue Percent of Non-Royalty Sublicense Revenues Payable to CSMC Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 35% After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 10% After submission of an NDA/BLA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 8% After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 5% Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC a percentage of these Non- Non Royalty Sublicense Revenues according to the following schedule: Date Timing of Receipt of Non-Royalty Sublicense Revenue Percent of Non-Royalty Sublicense Revenues Payable to CSMC Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 35% After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 10% After submission of an NDA/BLA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 8% After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 5% Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g4.2(h) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC (on behalf of Licensors) by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC (on behalf of Licensors) a percentage of these Non- Non-Royalty Sublicense Revenues according to the following schedule: Date of Receipt of Non-Royalty Sublicense Revenue (from Effective Date) Percent of Non-Royalty Sublicense Revenues Payable to CSMC Licensors Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 35% After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 10% After submission of an NDA/BLA NDA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product therefor 8% After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction NDA for a Product 5% Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash kind to CSMC (on behalf of Licensors) in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g4.5(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC (on behalf of Licensors) and Licensee (which agreement may be a condition of approval under Section 2.2).

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC a percentage of these Non- Non-Royalty Sublicense Revenues according to the following schedule: Date of Receipt of Non-Royalty Sublicense Revenue Percent of Non-Royalty Sublicense Revenues Payable to CSMC Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 35% After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 10% After submission of an NDA/BLA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 8% After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 5% Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g4.2(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC a percentage of these Non- Royalty Sublicense Revenues according to the following schedule: Date of Receipt of Non-Royalty Sublicense Revenue (from Effective Date) Percent of Non-Royalty Sublicense Revenues Payable to CSMC Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 3535 % After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 1010 % After submission of an NDA/BLA NDA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 8therefor 8 % After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction NDA for a Product 55 % Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash kind to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g4.4(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).

Non-Royalty Sublicense Revenues. Any and all “Non-Royalty Sublicense Revenues” shall be reported and paid to CSMC by Licensee as set forth below within sixty (60) days of receipt by Licensee. Licensee shall pay to CSMC a percentage of these Non- Non-Royalty Sublicense Revenues according to the following schedule: Date of Receipt of Non-Royalty Sublicense Revenue Percent of Non-Royalty Sublicense Revenues Payable to CSMC Prior to receipt of FDA authorization of an Investigational New Drug (“IND”) application or equivalent regulatory agency authorization in another jurisdiction for a Product 3535 % After receipt of FDA authorization of an IND application for a Product or equivalent regulatory agency authorization in another jurisdiction, but prior to submission of a New Drug Application (“NDA”) or Biologics License Applications (BLA) to the FDA or equivalent regulatory agency in another jurisdiction 1010 % After submission of an NDA/BLA for a Product but prior to receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 88 % After receipt of FDA approval of an NDA/BLA or equivalent regulatory agency approval in another jurisdiction for a Product 55 % Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g4.2(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).